Question explored with the scientific record
Which pertussis vaccine is more effective? Whole cell or acellular? Which of the two is recommended for children, if any?
The short version: whole-cell pertussis vaccines are more effective at preventing infection and transmission, but they cause more frequent and more severe side effects. Acellular vaccines are less effective and their protection wanes faster, but they are safer per dose.
The choice depends on how you weigh efficacy against safety. A 2003 systematic review found that whole-cell DTP efficacy ranged from 37% to 92%, while acellular vaccines with three or more components reached 80-84% [3]. That range for whole-cell hides a problem: the older vaccines were not standardized. Some batches worked well, others barely at all. A Canadian study from 1995-2003 showed that children who received whole-cell vaccine had a time to disease of about 40-47 months, versus only 14-17 months for acellular vaccine [2]. That means acellular protection wears off much faster.
| Vaccine type | Efficacy range (against disease) | Time to disease (months) | Fever rate | Seizure risk per million doses |
|---|---|---|---|---|
| Whole-cell DTP | 37-92% [3] | 36-47 [2] | 30-76% [5] | 2.5 [4] |
| Acellular DTaP | 67-84% (≥3 components) [3] | 14-17 [2] | 2.7% [5] | 0.65 [4] |
The safety difference is not small. Whole-cell DTP contains about 100 times more endotoxin than acellular vaccine: 79,400 EU/ml versus 780 EU/ml [4]. The same study found whole-cell DTP had a 3.9 times higher risk of seizures, 2.3 times higher risk of disabilities, and 2.3 times higher risk of death per million doses [4]. Japan switched from whole-cell to acellular in 1981 and saw deaths per million doses drop from 2.27 to 0.16 [5].
The global resurgence in 2024 is concentrated in countries using acellular vaccines [1]. Denmark, Finland, England, and the US all show sharp increases, especially in children aged 5-14 who received acellular vaccines as infants [1]. Argentina, which still uses whole-cell vaccines, did not report similar surges [1].
Every major national health agency, including the CDC and WHO, now recommends acellular vaccines for children, because its better safety profile is considered worth the trade-off in shorter duration of protection. I agree with that recommendation for the primary series in infancy. The risk from the old whole-cell vaccines is real and well-documented.
My call: acellular DTaP is the right choice for infants, despite weaker protection, because whole-cell DTP carries a genuinely higher risk of fever, seizures, and serious reactions. Confidence: high.
Sources used 5
-
Global Incidence of Pertussis After the COVID-19 Pandemic
A multinational epidemiological assessment of pertussis incidence after the COVID-19 pandemic, revealing a global resurgence with notable age shifts, vaccine- and lineage-related changes, and implications for vaccination strategies and the need for vaccines that block transmissi…
DOI: 10.1001/jamanetworkopen.2025.45963 -
Pertussis in Rural Populations of Saskatchewan (1995 to 2003)
A population-based descriptive epidemiological study (1995–2003) describing pertussis incidence, seasonality, and differences between rural and urban populations in Saskatchewan, including vaccine-type effects on time-to-disease and implications for public health surveillance.
DOI: 10.1007/BF03405228 -
Systematic review of the effects of pertussis vaccines in children
This systematic review assesses the efficacy and safety of whole-cell and acellular pertussis vaccines in children, finding that all tested vaccines are effective, with whole-cell vaccines showing variable efficacy and a higher incidence of adverse events compared to acellular v…
DOI: 10.1016/s0264-410x(02)00770-3 -
Serious neurological conditions following pertussis immunization: an analysis of endotoxin levels, the vaccine adverse events reporting system (VAERS) database and literature review
This study investigates the risks of serious neurological conditions following whole-cell DTP vaccination compared to acellular DTaP vaccination, revealing that whole-cell DTP contains significantly higher endotoxin levels and is associated with a greater incidence of adverse re…
DOI: 10.1080/1363849021000054031 -
Pertussis Vaccines in Japan
Development and evaluation of a Japanese acellular pertussis vaccine showing substantially fewer adverse reactions than whole-cell vaccines with comparable protective efficacy, supported by a field trial and national surveillance indicating reduced pertussis incidence and potent…
DOI: 10.1111/j.1442-200x.1988.tb02512.x